Meet Trevena: A talk with CEO Maxine Gowen
Trevena (TRVN) is a clinical-stage biopharmaceutical company focused on the development of therapeutics that target G protein coupled receptors, or GPCRs, for the treatment of acute pain. In an exclusive interview with The Fly, the company's CEO Maxine Gowen talked about the company's ongoing clinical trials, upcoming events, market opportunity for its lead drug and much more. Here are some of the highlights: OLICERIDINE TRIALS ON TRACK: Phase 3 trials for the company's primary candidate Oliceridine, or TVR130, for the treatment of moderate to severe acute pain continue to be on track, with top line data still expected in the first quarter of 2017, CEO Gowen said. According to the executive, Trevena believes it will have sufficient data to support a broad label indication for Oliceridine, without the need to do any further trials aside from the ongoing APOLLO studies in bunionectomy and abdominoplasty and the ATHENA multi procedure trial. A bunionectomy is a surgical procedure to remove a bunion, while an abdominoplasty is a cosmetic surgery procedure used to make the abdomen thinner, more commonly known as a "tummy tuck." LESS ADVERSE EFFECTS: Noting that millions of U.S. patients are treated with an intravenous opioid and have to deal with opioid related adverse effects, Gowen explained that Oliceridine was designed specifically to overcome these adverse events. The executive pointed out that Trevena's clinical data, so far, has shown that Oliceridine can deliver a very rapid pain relief at similar levels to morphine, but with fewer opioid related adverse effects, which she believes will improve hospital care for patients. OTHER PRODUCT CANDIDATES: Aside from Oliceridine, Trevena is developing TRV250 for the treatment of episodic migraine and TRV734 for moderate to severe acute and chronic pain. The CEO expects to submit an Investigational New Drug, or IND, application for '250 to the Food and Drug Administration later this year, which should enable the company to start clinical trials next year. Regarding TRV734, Gowen noted that it makes sense to evaluate a potential partnership as the commercialization of the drug for chronic pain is not "an ideal fit" for the company given Trevena's hospital and specialist focus. CAPITAL TO FUND OPERATIONS INTO 2018: The executive told The Fly that the company maintains its prior guidance, estimating to have enough capital to fund operations into 2018, adding that the company does not discuss plans for future financing. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. A more detailed version of this interview to follow.